Ophthalmic composition containing active vitamin D
    1.
    发明授权
    Ophthalmic composition containing active vitamin D 失效
    含有活性维生素D的眼用组合物

    公开(公告)号:US06500813B1

    公开(公告)日:2002-12-31

    申请号:US09678256

    申请日:2000-10-03

    IPC分类号: A61K3159

    摘要: An ophthalmic composition comprises active vitamin D as an effective component and is used for preventing deterioration of the optical transparency, occurrence of high intraocular pressure diseases or defective sight, observed after an ophthalmic operation, due to hyperplasia of the anterior ocular cells in the tissues damaged by the ophthalmic operation, which are in course of a healing process, and/or excess production of cellular materials. The ophthalmic composition can be dropped in the eye after operations such as those for cataract, for transplantation of intraocular lenses and for cornea to maintain the intraocular transparency of the anterior ocular region, to control the hyperplasia of the anterior ocular cells in the tissues damaged by the ophthalmic operation, which are in course of a healing process, and/or excess production of cellular materials and to thus prevent any reduction of visual acuity.

    摘要翻译: 一种眼用组合物包含活性维生素D作为有效成分,用于防止眼部手术后观察到的光学透明度降低,高眼内压疾病或视力缺陷,由于组织中前眼细胞的增生受损 通过眼科手术,其处于愈合过程的过程中和/或细胞材料的过量产生。眼科组合物可以在诸如白内障手术,眼内透镜移植和角膜维持等手术后滴入眼中 眼前区域的眼内透明度,以控制由眼科手术损伤的组织中的前眼细胞的增生,其在愈合过程中,和/或细胞材料的过量产生并因此防止任何还原 的视力。

    Corneal sponge and method of use
    3.
    发明授权
    Corneal sponge and method of use 失效
    角膜海绵及使用方法

    公开(公告)号:US5368590A

    公开(公告)日:1994-11-29

    申请号:US52619

    申请日:1993-04-27

    申请人: Seiji Itoh

    发明人: Seiji Itoh

    摘要: A sponge which is placed on the cornea for laser treatment to absorb unavoidable exuded fluids from the peribulber. This corneal sponge offers protectiveness, convenience and improved effectiveness of corneal laser therapy. The corneal sponge has a surgical space to expose the portion of the cornea to be treated, and is marked for accurate and easy alignment of the microscopic field. The corneal sponge contains a cool ophthalmic solution used to minimize inflammatory response which may cause postoperative complications such as corneal haze and inconsistent corneal refractions.

    摘要翻译: 海绵放置在角膜上用于激光治疗以从周围纤维吸收不可避免的渗出液。 角膜海绵提供角膜激光治疗的保护性,方便性和改善的效果。 角膜海绵具有外科空间以暴露要治疗的角膜的部分,并且被标记为准确且容易地对准微观区域。 角膜海绵含有用于最小化炎症反应的凉爽眼用溶液,其可引起术后并发症,例如角膜混浊和不一致的角膜折射。

    Carburized and quenched member and method for production thereof
    5.
    发明申请
    Carburized and quenched member and method for production thereof 审中-公开
    渗碳淬火件及其制造方法

    公开(公告)号:US20050173026A1

    公开(公告)日:2005-08-11

    申请号:US10473716

    申请日:2002-12-25

    IPC分类号: C23C8/22 C23C8/80

    CPC分类号: C23C8/22 C23C8/80

    摘要: A carburizing and hardening method enhances strength while sufficiently reducing hardening strain, without increasing the production cost, and a carburized and hardened member produced thereby. The raw material is an alloy steel which contains Fe as a main component, 0.10 to 0.50 wt. % C and 0.50 to 1.50 wt. % Si and having a hardenability J, based on an end quenching test, in a range of 35 to 50 (at 12.5 mm). After the raw material is formed into the desired shape, a carburized layer is formed by carburizing in an oxidation inhibiting atmosphere. After the carburizing, quenching is performed with cooling, uninterrupted by temperature rise, from a pearlite transformation point (A1 point) to a martensite transformation start point (Ms point), and with a severity of quenching H in a range of 0.01 to 0.08 (cm−1).

    摘要翻译: 渗碳硬化方法提高强度,同时充分降低硬化应变,而不增加生产成本,并且由此生产的渗碳硬化构件。 原料是含有Fe作为主要成分的合金钢,0.10〜0.50重量% %C和0.50〜1.50wt。 %Si,并且基于终止淬火试验具有淬透性J,在35〜50(12.5mm)的范围内。 在原料形成所需形状之后,通过在氧化抑制气氛中渗碳形成渗碳层。 渗碳后,从珠光体相变点(A1点)到马氏体相变开始点(Ms点)的冷却不间断地进行淬火淬火,淬火强度H在0.01〜0.08的范围内( cm -1)。

    Plastic display building device for cans
    9.
    发明授权
    Plastic display building device for cans 失效
    塑料显示屏罐装建筑装置

    公开(公告)号:US4582447A

    公开(公告)日:1986-04-15

    申请号:US506039

    申请日:1983-06-20

    申请人: Seiji Itoh

    发明人: Seiji Itoh

    摘要: An adaptor structure for connecting a plurality of beverage cans together in selected configurations comprising a base plate with connector members on a first side thereof, a can-receiving socket on the opposite side thereof and spacer members within said socket. The cans have end recesses in which the spacer members seat when an adaptor is coupled to a can to form a strong, stable connection. Cans are assembled end-to-end with back-to-back adaptors at the end interfaces, the adaptors being connected to each other by the connector members.

    摘要翻译: 一种用于将多个饮料罐连接在一起的适配器结构,其选择的配置包括在其第一侧上具有连接器构件的基板,在其相对侧上的可容纳插座和位于所述插座内的隔离构件。 罐具有端部凹槽,当适配器联接到罐体上时,间隔件构件就位于其中,以形成牢固且稳定的连接。 罐在端部接口处以背对背适配器端对端组装,适配器通过连接器构件相互连接。

    Ophthalmological composition comprising activated vitamin D
    10.
    发明授权
    Ophthalmological composition comprising activated vitamin D 失效
    包含活化的维生素D的眼科组合物

    公开(公告)号:US06248732B1

    公开(公告)日:2001-06-19

    申请号:US08913522

    申请日:1997-11-24

    IPC分类号: A61K3159

    摘要: An ophthalmic composition comprises active vitamin D as an effective component and is used for preventing deterioration of the optical transparency, occurrence of high intraocular pressure diseases or defective sight, observed after an ophthalmic operation, due to hyperplasia of the anterior ocular cells in the tissues damaged by the ophthalmic operation, which are in course of a healing process, and/or excess production of cellular materials. The ophthalmic composition can be dropped in the eye after operations such as those for cataract, for transplantation of intraocular lenses and for cornea to maintain the intraocular transparency of the anterior ocular region, to control the hyperplasia of the anterior ocular cells in the tissues damaged by the ophthalmic operation, which are in course of a healing process, and/or excess production of cellular materials and to thus prevent any reduction of visual acuity.

    摘要翻译: 一种眼用组合物包含活性维生素D作为有效成分,用于防止眼部手术后观察到的光学透明度降低,高眼内压疾病或视力缺陷,由于组织中前眼细胞的增生受损 通过眼科手术,其处于愈合过程的过程中和/或细胞材料的过量产生。眼科组合物可以在诸如白内障手术,眼内透镜移植和角膜维持等手术后滴入眼中 眼前区域的眼内透明度,以控制由眼科手术损伤的组织中的前眼细胞的增生,其在愈合过程中,和/或细胞材料的过量产生并因此防止任何还原 的视力。